Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

32.53
+0.11000.34%
Pre-market: 32.990.4600+1.41%04:16 EDT
Volume:591.30K
Turnover:19.11M
Market Cap:1.87B
PE:12.96
High:32.69
Open:32.01
Low:31.84
Close:32.42
Loading ...

Harmony Biosciences Holdings, Inc. : Deutsche Bank Cuts Target Price to $52 From $55

THOMSON REUTERS
·
20 Feb

Concerns Over Harmony Biosciences: FDA Setback, Patent Risks, and High-Risk Pipeline

TIPRANKS
·
20 Feb

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Benzinga
·
20 Feb

Harmony Biosciences Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Harmony Biosciences: Buy Rating Affirmed Despite FDA Setback, Strong Growth Potential in Pitolisant Franchise and Pipeline Opportunities

TIPRANKS
·
20 Feb

BUZZ-Harmony Biosciences drops after FDA refuses to review hypersomnia drug

Reuters
·
20 Feb

Harmony Biosciences Is Maintained at Buy by Needham

Dow Jones
·
20 Feb

BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia

Reuters
·
19 Feb

Harmony Biosciences: FDA Turns Away Idiopathic Hypersomnia Application

Dow Jones
·
19 Feb

Harmony Biosciences : Needham Cuts Target Price to $50 From $52

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Receives US FDA's Refusal to File Letter Related to Application for Pitolisant in Idiopathic Hypersomnia

MT Newswires Live
·
19 Feb

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Holdings Inc - Receives FDA Refusal to File Letter for Pitolisant

THOMSON REUTERS
·
19 Feb

Harmony Biosciences -on Track to Initiate a Phase 3 Registrational Trial of Pitolisant Hd in Ih in Q4 2025, With a Target Pdufa Date in 2028

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Holdings Inc - 2025 Net Revenue Guidance Remains Unchanged at $820-$860 Million

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Business Wire
·
19 Feb

Press Release: Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Dow Jones
·
18 Feb

HRMY or ONC: Which Is the Better Value Stock Right Now?

Zacks
·
18 Feb

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Zacks
·
14 Feb

Harmony Biosciences Holdings, Inc (HRMY): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb